All In Biotech

Drug Trial Radar · NCT07746479

A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )

A Multicenter, Open-Label, Single-Arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of LZM012 Injection in Patients With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

244

Actual

Start

Jun 23, 2025

Primary completion

Jan 26, 2026

Study completion Jan 26, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Multicenter, Open-Label, Single-Arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of LZM012 Injection in Patients With Moderate to Severe Plaque Psoriasis.

Conditions

  • Psoriasis

Interventions

  • LZM012Biological

    Recombinant anti-human IL-17A/F humanized monoclonal antibody injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PASI100 response rateTime frame: At week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Dermatology Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.